Table 2.

Comparison of treatment groups for primary and secondary outcomes

VariableLosartan Group (n=77)Placebo Group (n=76)OR or HR (95% CI)P Value
Primary endpoint
 Doubling of interstitium or ESRD from IF/TA6/4712/44OR, 0.39 (0.13–1.15)0.08
 Doubling of interstitium2/474/44OR, 0.44 (0.08–2.56)0.42
 ESRD from IF/TA4/478/44OR, 0.42 (0.12–1.50)0.22
Secondary endpoints
 Doubling of interstitium or any ESRD7/4815/47OR, 0.36 (0.13–0.99)0.05
 Doubling of interstitium2/474/44OR, 0.44 (0.08–2.56)0.42
 All cause ESRD5/4811/47OR, 0.38 (0.12–1.20)0.09
Time to death any time after randomization10/7714/76HR, 1.38 (0.62–3.20)0.44
Time to earliest of death, any ESRD, or doubling of creatinine19/7724/76HR, 1.37 (0.75–2.53)0.30
 Doubling of creatinine9/7712/76HR, 7.28 (2.22–32.78)<0.01
 All cause ESRD4/775/76HR, 0.54 (0.10–2.47)0.42
 Death6/777/76HR, 0.90 (0.28–3.13)0.85
  • HR, hazard ratio.